Related articles

Zilurgisertib (Atebrioz)

Approved F.O.P. therapy marketed as Atebrioz; inhibits the ALK2 protein involved in directing bone growth.

• New Treatments Offer Hope for Patients with Runaway Bone Disorder F.O.P.